Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ. “Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.” Journal of Urology, July 2009; 182: 101. Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841
Loeb S. “Editorial Comment on: Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-Institution Active Surveillance Cohort.” Urology 2014; 83 (1): 38-19. PMID: 24246328 Link: http://www.ncbi.nlm.nih.gov/pubmed/24246328
Vellekoop A and Loeb S. “Editorial Comment on A Single Dose of 240 mg Gentamicin During Transrectal Prostate Biopsy Significantly Reduces Septic Complications.” Urology 2013 epub August. Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=23992969
Loeb S. “Editorial Comment on ‘Screening Rectal Culture to Identify Fluoroquinolone-Resistant Organisms Before Transrectal Prostate Biopsy: Do the Culture Results Between Office Visit and Biopsy Correlate?” Urology 2013; 82: 71. Link: http://www.ncbi.nlm.nih.gov/pubmed/23806392
Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ. “Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.” BJU International, February 2009 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451
Loeb S, Roehl KA, Thaxton CS, and Catalona WJ. “Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.” Urology, July 2008; 72: 143. Link: http://www.ncbi.nlm.nih.gov/pubmed/18436287
Tosoian J and Loeb S. “PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.” TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931. Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581
Catalona WJ and Loeb S. “Commentary on the Recommendations of The American College of Preventive Medicine on Prostate Cancer Screening.” Medscape Urology (online)
Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ. “Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.” Journal of Uroloy 2012 epub November. PMID: 23159463. Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463
Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M. “Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.” BJU International, June 2008; 101: 1503. Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626
Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. “Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.” Urology 2007; 70: 1117. Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030
Loeb S and Carter HB. “Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.” Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583. Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470
Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ. “Underdiagnosis and Overdiagnosis of Prostate Cancer.” Journal of Urology 2007; 178: 88. Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308
Loeb S and Catalona WJ. “What to do with an abnormal PSA test.” The Oncologist, March 2008; 13: 299. Link: http://www.ncbi.nlm.nih.gov/pubmed/18378540
Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, and Catalona WJ. “Characteristics of Prostate Cancers Detected at Prostate-Specific Antigen Levels Less than 2.5 ng/ml.” Journal of Urology, June 2009; 181: 2515. Link: http://www.ncbi.nlm.nih.gov/pubmed/19371879
Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ. “Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.” Urology October 2011; 78: 970 .e 15-20. PMID: 21820706. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/
Loeb S. “Prostate Cancer: Is PSA Velocity Useful?” Nature Reviews Urology, June 2009; 6: 305. Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408
Loeb S, Chan DW, Sokoll L, Kan D, Mikolajczyk SD, Maggiore J, Mondo DM, Griffin CR, and Catalona WJ. “PSA Standardization Bias Could Affect Clinical Decision-making.” Journal of Urology, November 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18801532
Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ. “Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.” Journal of Urology, August 2010; 184: 501. Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408
Loeb S. “Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use.” BJU International June 2012; 109: 1785-6. PMID: 22040375. Link: http://www.ncbi.nlm.nih.gov/pubmed/22040375
Loeb S. “Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?” European Urology 2014 Nov epub. PMID: 25465339. Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339
Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ. “Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?” Journal of Urology, January 2007; 177: 102. Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013
Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ. “Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression” Urology, July 2006; 68: 99. Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410
Loeb S and Carter HB. “Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.” European Urology, February 2009; 55: 523. Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535
Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. “Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.” Urology December 2007; 70: 1117. Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030
Helfand BT, Loeb S, Kan D, Catalona WJ. “Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.” BJU International, June 2010 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552
Loeb S, Van den Heuvel S, Zhu X, Bangma CH, Schroder FH, and Roobol MH. “Reply from the Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy- Thou Shall Think Twice.” Eur Urol. In press. DOI:10.1016/j.eururo.2012.01.055: Considerations for Prostate Biopsy Decisions.” European Urology; 2012 March 8 epub. Link: http://www.europeanurology.com/article/S0302-2838%2812%2900307-7/fulltext/reply-from-authors-re-alexandre-r-zlotta-robert-k-nam-to-biopsy-or-not-to-biopsy-x02014-thou-shall-think-twice-eur-urol-2012-61-1115-x02013-7
Loeb S. “Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’” Urology Practice 2014 May; 1: 20.
Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB. “The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.” European Urology, November 2008 54: 978. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/
Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ. “Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” Urology, June 2007; 69: 1143. Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203
Loeb S. Editorial Comment on “Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.” Urology 2015; 85: 170. PMID: 25530380. Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379
Loeb S and Catalona WJ. “Prostate cancer screening: Where are we now?” Contemporary Urology, May 2007 Link:
Loeb S and Catalona WJ. “PSA as a Screening Test for Prostate Cancer.” ACP Observer, April 2007
Loeb S and Catalona WJ. “Advances in Prostate Cancer Testing.” Clinical Laboratory News, March 2007; 33: 12.
Catalona WJ and Loeb S. “PSA Is an Effective Marker for Prostate Cancer.” AUANews, January 2007 (Part 1) and February 2007 (Part 2) Link:
Catalona WJ and Loeb S. “More Effective Use of PSA” Urologic Oncology: Seminars and Original Investigations, May-June 2006; 24: 177.
Loeb S. “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.” Urology August 2011; 78: 255. PMID: 21820566. Link: http://www.ncbi.nlm.nih.gov/pubmed/21820566
Loeb S and Partin AW. “Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.” Reviews in Urology 2011; 13: 63. PMID: 21845110. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/
Makarov DV, Loeb S, Getzenberg RH, and Partin AW. “Biomarkers for Prostate Cancer.” Annual Reviews in Medicine, October 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298
Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ. “Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.” Urologic Oncology: Seminars and Original Investigations, November-December 2006; 24: 465. Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126